Comparison between human leucocyte antigen B27 (HLA-B27)-positive and HLA-B27-negative patients and between patients with and without inflammation on magnetic resonance imaging of the sacroiliac joints in the early spondyloarthritis clinic cohort
HLA-B27 | Inflammation on MRI | HLA-B27 or inflammation | ||||
---|---|---|---|---|---|---|
Present(n = 31) | Absent(n = 37) | Present(n = 22) | Absent(n = 46) | Present(n = 37) | Absent(n = 31) | |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; IBP, inflammatory bowel pain; MRI, magnetic resonance imaging; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; SpA, spondyloarthritis. | ||||||
Extra-spinal SpA features: asymmetric arthritis, Achilles tendinitis, dactylitis, inflammatory bowel disease, acute anterior uveitis and psoriasis. | ||||||
Data are percentages unless otherwise indicated. | ||||||
Male | 52 | 24 | 64 | 24 | 54 | 16 |
Inflammation on MRI | 52 | 16 | NA | NA | 59 | 0 |
HLA-B27 positive | X | X | 73 | 33 | 84 | 0 |
History or presence of IBD | 7 | 23 | 5 | 20 | 5 | 26 |
History or presence of acute anterior uveitis | 19 | 11 | 14 | 15 | 19 | 10 |
History or presence of psoriasis | 13 | 32 | 18 | 26 | 16 | 32 |
Family history of ankylosing spondylitis | 48 | 27 | 32 | 39 | 54 | 55 |
Raised acute-phase reactants | 45 | 38 | 46 | 44 | 51 | 31 |
Improvement on NSAIDs (%) | 81 | 41 | 91 | 44 | 84 | 29 |
Mean BASDAI (SD) | 3.6 (1.8) | 3.7 (4.4) | 3.8 (2.1) | 3.6 (2.2) | 3.7 (1.9) | 3.6 (3.3) |
Mean BASFI (SD) | 2.5 (1.8) | 2.7 (2.3) | 2.7 (2.0) | 2.6 (2.2) | 2.6 (1.8) | 2.6 (2.2) |
Checklist IBP | ||||||
<5 criteria present | 30 | 57 | 36 | 48 | 35 | 61 |
5 criteria present | 70 | 43 | 64 | 52 | 65 | 39 |
Presence of extra-spinal SpA features | ||||||
0 SpA features | 39 | 24 | 36 | 28 | 30 | 19 |
1 or 2 SpA features | 55 | 67 | 55 | 65 | 62 | 74 |
⩾3 SpA features | 6 | 8 | 9 | 7 | 8 | 6 |